Agenix teams with Arrayjet on POCT project
Agenix (ASX:AGX) has partnered with Scotland’s Arrayjet Limited to develop a multiplex microarray test system.
The companies have signed a cooperation and cross-licensing agreement to create a point of care test (POCT) combining Agenix’s DiagnostIQ test platform with Arrayjet’s planar microarray technology. The eventual goal is to develop DiagnostIQ into a multiplex testing and screening system.
Agenix and Arrayjet plan to fund the development activities in part by research grants and R&D Tax Incentive rebates.
DiagnostIQ is a POCT platform technology originally developed by Tyrian Diagnostics. Agenix acquired exclusive royalty-free rights to use the platform for human applications in a $500,000 deal with Tyrian signed in October 2012. Bayer CropScience has the right to use the platform for agricultural purposes.
Arrayjet’s technology involves non-contact inkjet printing of multiplexed planar microarrays.
Agenix CEO Nick Weston said the collaboration has the potential to produce a platform that fulfils an unserved niche.
“There is a high unmet medical need for a platform able to do multiplexed affinity-based assays in low-resource or mobile settings,” he said.
Dr Ian McWilliam, CEO of Arrayjet, added that the companies eventually aim to “offer customers an end-to-end process, whereby they can rapidly translate a novel biomarker profile into a diagnostic tool presented on a reformatted version of DiagnostIQ”.
Agenix (ASX:AGX) shares were trading unchanged at $0.025 as of around 1 pm on Monday.
3D-printed films provide targeted liver cancer treatment
Researchers have created drug-loaded, 3D-printed films that kill more than 80% of liver cancer...
Using your brain at work may ward off cognitive impairment
The harder your brain works at your job, the less likely you may be to have memory and thinking...
Repurposed drugs show promise in heart muscle regeneration
The FDA-approved medications, when given in combination, target two proteins that regulate the...
